- 英文名称
- Linaclotide acetate
- 分子式
- C61H83N15O23S6
- 分子量
- 1586.78
- 中文别名
- 利那洛肽; 林可洛德; 利那洛肽 醋酸盐; L-半胱氨酰基-L-半胱氨酰基-L-α-谷氨酰基-L-酪氨酰基-L-半胱氨酰基-L-半胱氨酰基-L-天冬酰胺酰基-L-脯氨酰基-L-丙氨酰基-L-半胱氨酰基-L-苏氨酰基甘氨酰基-L-半胱氨酰-L-酪氨酸,环状(1→6),(2→10),(5→13)- 三(二硫化物)乙酸盐; ((3S,6R,15R,20R,23S,26R,29R,32R,37R,40S,45aS)-32-氨基-40-(2-氨基-2-氧代乙基)-26-(2-羧乙基)-23-(4-羟基苄基)-9-((R)-1-羟乙基)-3-甲基-1,4,7,10,13,22,25,28,31,38,41,47-十二氧代四十氢-19H-37,20-(桥亚氨基甲桥)-6,29-(甲桥二硫杂甲桥)吡咯并[2,1-s][1,2,27,28]四硫杂[5,8,11,14,17,20,23,32,35,38,41]十一氮杂环四十三碳-15-羰基)-L-酪氨酸 乙酸盐 (1:1); ((3S,6R,15R,20R,23S,26R,29R,32R,37R,40S,45aS)-32-Amino-40-(2-amino-2-oxoethyl)-26-(2-carboxyethyl)-23-(4-hydroxybenzyl)-9-((R)-1-hydroxyethyl)-3-methyl-1,4,7,10,13,22,25,28,31,38,41,47-dodecaoxotetracontahydro-19H-37,20-(epiminomethano)-6,29-(methanodithiomethano)pyrrolo[2,1-s][1,2,27,28]tetrathia[5,8,11,14,17,20,23,32,35,38,41]undecaazacyclotritetracontine-15-carbonyl)-L-tyrosine compound with acetic acid (1:1); N-({(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-Amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-30-(4-hydroxybenzyl)-44-[(1R)-1-hydroxyethyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecaazatetracyclo[22.22.4.216,33.07,11]dopentacont-38-yl}carbonyl)-L-tyrosine acetate (1:1); L-Tyrosine, L-cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (1→6),(2→10),(5→13)-tris(disulfide), acetate (1:1); MD-1100 Acetate; MM-416775; Linaclotide impurity; Linzess; MM416775 MD-1100 acetate
- 用途
- 利那洛肽是一种有效和选择性的鸟苷酸环化酶C(guanylate cyclase C)激动剂；开发用于研究便秘型肠易激综合症(IBS-C)和慢性便秘。
